These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19890182)

  • 1. Spine care: evaluation of the efficacy and cost of emerging technology.
    Smith HE; Rihn JA; Brodke DS; Guyer R; Coric D; Lonner B; Shelokov AP; Currier BL; Riley L; Phillips FM; Albert TJ
    Am J Med Qual; 2009; 24(6 Suppl):25S-31S. PubMed ID: 19890182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining value in spine care.
    Rihn JA; Berven S; Allen T; Phillips FM; Currier BL; Glassman SD; Nash DB; Mick C; Crockard A; Albert TJ
    Am J Med Qual; 2009; 24(6 Suppl):4S-14S. PubMed ID: 19890180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the value of spine care.
    Rihn JA; Currier BL; Phillips FM; Glassman SD; Albert TJ
    J Am Acad Orthop Surg; 2013 Jul; 21(7):419-26. PubMed ID: 23818029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of hospice care.
    Robinson BE; Pham H
    Clin Geriatr Med; 1996 May; 12(2):417-28. PubMed ID: 8799358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
    Neumann PJ
    J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence, appropriateness, and technology assessment in cardiology: a case study of computed tomography.
    Redberg RF
    Health Aff (Millwood); 2007; 26(1):86-95. PubMed ID: 17211017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When is a cost-effectiveness claim valid? How much should the FDA care?
    Luce BR; Hillman AL
    Am J Manag Care; 1997 Nov; 3(11):1660-6. PubMed ID: 10178464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and effectiveness: approval and payment for Pulverizer.
    Riegelman R
    Md Med; 2002; 3(3):50-4. PubMed ID: 12214498
    [No Abstract]   [Full Text] [Related]  

  • 16. Evidence-based medicine and cost-effectiveness.
    Brown GC; Sharma S; Brown MM; Garrett S
    J Health Care Finance; 1999; 26(2):14-23. PubMed ID: 10605659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we afford to eliminate restenosis? Can we afford not to?
    Greenberg D; Bakhai A; Cohen DJ
    J Am Coll Cardiol; 2004 Feb; 43(4):513-8. PubMed ID: 14975456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions.
    Brown MM; Brown GC; Brown HC; Irwin B; Brown KS
    Curr Opin Ophthalmol; 2008 May; 19(3):202-7. PubMed ID: 18408494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
    Sorenson C
    Issue Brief (Commonw Fund); 2010 Jul; 91():1-14. PubMed ID: 20614655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.